A prospective outcomes and cost-effective analysis of surgery compared to stereotactic body radiation therapy for stage I non-small cell lung cancer
Central Institutional Review Board (IRB) approval was obtained under expedited review and deemed minimal risk to patients (WCG Clinical IRB00000533 Study 1171593). All participating sites obtained local IRB approval before study initiation. Informed consent was obtained from all patients prior to study entry.
Authors
- R. Geer
- Andrew S. Kennedy (ORCID: https://orcid.org/0000-0001-9761-2262)
- Dax Kurbegov
- Casey Martin (ORCID: https://orcid.org/0000-0003-3722-3147)
- Howard Burris
- David R. Spigel (ORCID: https://orcid.org/0000-0003-3215-9465)
- Laurie W. Cuttino
- Shanna A. Arnold Egloff (ORCID: https://orcid.org/0000-0002-6472-939X)
- Melissa L. Johnson (ORCID: https://orcid.org/0000-0001-9874-1314)
- Denis Gilmore
- Susan Garwood
- Tammy Baxter
- Casey Chollet-Lipscomb
- Meredith Mattlin
- Pratik Doshi (ORCID: https://orcid.org/0000-0003-0141-2691)
- David M. Randolph
- Jenifer L. Marks
- E.M. Osborne
Institutions
- Sarah Cannon Research Institute (GB)
- HCA Healthcare (US)
- EOSPACE (United States) (US)
- Sarah Cannon (US)
Publication Details
- Journal
- Radiation Oncology
- Published
- 2025-08-05
- DOI
- https://doi.org/10.1186/s13014-025-02699-4
- Primary Topic
- Lung Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- HCA Healthcare